ARTICLE | Distillery Therapeutics
Pulmonary
May 16, 2018 5:51 PM UTC
Cell culture studies identified a phenylbenzimidamide-based RNF5 inhibitor that could help treat CF in patients harboring the ΔF508 loss-of-function mutation in CFTR. In silico screening of a small mo...